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Abstract
Background: Sickle cell anemia is associated with a hypercoagulable state that may lead to alterations in a coagulation 
profile. Measurements of coagulation factors are known to have some predictive value for clinical outcome.
Objectives: To determine the coagulation profile of children with SCA in steady state and crisis and compare it with 
those with normal HbAA genotype.
Materials and Methods: This is a prospective observational study involving 50 children with SCA in steady state, 50 
in crises, and 50 with HbAA genotype, carried out from June to October 2009. All the values of coagulation profile were 
matched for age and sex.
Results: The mean Prothrombin time (PT) (12.5 ± 1.2 secs), Activated partial thromboplastin time (aPTT) 
(41.6 ± 1.0 secs), and Thrombin time (TT) (12.3 ± 1.2 secs) of subjects with SCA in steady state as well as those during 
crises [PT (12.6 ± 1.8 secs), aPTT (45.6 ± 1.3 secs), TT (12.5 ± 1.7 secs)] were significantly prolonged compared 
to those of subjects with HbAA genotype. The mean bleeding time (BT) of 3.4 ± 1.0 mins was significantly shorter in 
children with SCA in steady state compared to those with HbAA genotype (3.7 ± 1.1 mins), (P < 0.038).
Conclusion: Coagulation profile of patients with SCA is prolonged both in steady state and during crisis and when 
compared to those with HbAA genotype, though all values are within normal range.
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Introduction
Sickle cell anemia (SCA) is a genetic hematological disorder 
characterized by red blood cells that assume an abnormal 
rigid, sickle shape.[1] This hereditary disorder contributes 
the equivalent of 3.4% mortality in children aged under 5 
worldwide or 6.4% in Africa.[2]
Sickle cell disorders were originally found in the tropics 
and subtropics but are now common worldwide due to 
migration of people from the tropical to temperate zone.[2] 
The prevalence of SCA in Nigeria ranges from 0.4% to 3% 
affecting about 20 per thousand new borns.[3] About 85% 
of sickle cell disorders and over 70% of all affected births 
occur in Africa.[4] It is noted that at least 5.2% of the world 
population carry a significant trait.[5]
SCA is associated with a hypercoagulable state that may 
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contribute to certain morbidities such as vaso-occlusion 
and cerebrovascular accidents.[5] It is noted that decreased 
levels of natural anticoagulant proteins are observed in SCA 
and even more so in vaso-occlusive crisis.[6,7] These reduced 
levels may be a consequence of chronic consumption arising 
from increased thrombin generation which occurs in the 
vascular endothelium.[8]
Patients with this disease suffer from a variety of clinical 
events associated with small and large vessel occlusion, 
including vaso-occlusive painful episodes, strokes, and 
acute chest syndrome.[9] Nduka et al.[5] noted 25% of cases of 
vaso-occlusion among patients with SCA while Westerman 
and colleague[6] observed pulmonary infarction in one out 
of every six patients with this disorder. Such events may 
be associated with derangements of plasma and cellular 
haemostatic mechanisms that may impart a thrombogenic 
tendency to this disorder.[9] Reported changes include 
increases in thrombin generation, platelet activation, 
decreased levels of circulating anticoagulants, and contact 
factors.[10] These changes may be due to shortened platelet 
survival, increased plasma levels of adenosine diphosphate 
and epinephrine, and decreased levels of circulating 
anticoagulants such as protein C and S.[10] These proteins are 
serine proteases whose activity are modulated by naturally 
occurring plasma inhibitors. They are key inhibitors of the 
blood coagulation system.[10]
Measurements of such coagulation factors are known 
to have some predictive value for clinical outcome. 
For instance, an increase in fibrinolytic activity has 
been reported to correlate with frequency of painful 
episodes.[11] This increased fibrinolytic activity may be due 
to inhibition of the binding of protein S to β-2 glycoprotein 
1 by antiphospholipid antibodies. Besides, higher levels 
of thrombin and prothrombin generation have also been 
reported in patients with strokes and vaso-occlusive crisis.[11]
This study therefore aims at determining the actual value 
of some coagulation profiles (PT, APTT, TT, Platelet count, 
Bleeding time) among patients with SCA in steady state and 
crises in this environment and compare with subjects with 
normal hemoglobin genotype. The findings from this study 
may add to the increasing knowledge of this challenging 
disease and may help to improve management of children 
with this disorder since there has not been much study 
among children in this locality. In addition, this study would 
also help in establishing baseline values of coagulation 
indices among SCA patients in steady state.
Materials and Methods
Study area
The study was carried out at the Children emergency room 
(CHER), Children’s outpatient (CHOP), and Consultants 
Paediatric clinics (CPC) of the Paediatrics Department 
of the University of Nigeria Teaching Hospital (UNTH) 
Ituku-Ozalla, Enugu, Nigeria. UNTH has a total bed space 
of 800 and provides specialized services in the major fields 
of medicine. It is a referral center for various health centers 
in Enugu state and environs. The Paediatrics Department 
comprises the children’s outpatient clinic (CHOP), the 
children emergency room (CHER), the general ward, and 
the new born special care unit (NBSCU).
Study population
There are about 700 children registered at the sickle cell 
clinic of UNTH, Enugu, with an average of 5 new patients 
a month. The clinic runs on Mondays with a weekly 
attendance of between 15 and 20 patients. It is run by 
3 Consultants, 2 Senior Registrars, and 4 Registrars.
The subjects studied included known SCA patients aged 
between 6 months and 18 years considered clinically to be 
in bone pain crisis as defined by Quirolo et al. as bone or 
joint pains in a single or multiple sites needing analgesics 
or hospitalization.[1] The stable patients were those with 
HbSS who had been apparently well for a minimum of 
4 weeks before recruitment.[1] Patients excluded include 
those with any type of infective illness and any patient 
with recent blood transfusion during the preceding 
3 months.[12,13]
The control population were children who were apparently 
healthy with normal hemoglobin genotype (HbAA) 
confirmed by hemoglobin electrophoresis coming for follow 
up after recovery from an acute illness like malaria and 
upper airway disease.
Children with SCA who were attending the sickle cell clinic 
or presented at the children emergency ward who fulfilled 
the inclusion criteria were consecutively recruited into the 
study. For the control group, the same method was used to 
recruit apparently healthy children (with HbAA genotype 
confirmed by hemoglobin electrophoresis) coming for 
follow up.
Ethical clearance for the study was obtained from the 
Research and Ethical Committee of the University of 
Nigeria Teaching Hospital. A written consent was obtained 
from the parents/caregivers of the subjects and controls after 
explaining to them, in detail, the objectives of the study as 
well as the method of specimen collection.
Determination of PT, APTT, TT, platelet count, and 
bleeding time
Prothrombin time was ascertained by delivering 0.1 ml of 
plasma into a glass tube placed in a water bath with 0.1 ml 
of thromboplastin and calcium (a saline brain extract 
containing tissue factor and a lipoprotein). Activated 
partial thromboplastin time in kaolin was done by mixing 
equal volumes of the phospholipids reagent and the kaolin 
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suspension. Thrombin time was done by adding 0.1 ml 
thrombin solution to 0.2 ml of control plasma in a glass tube 
at 37°C, while the activity was timed with the stopwatch.[12]
Platelet count and hemoglobin concentration were analyzed 
using automated Sysmex KX-21N model.[12] Bleeding time 
was estimated using the Ivy’s method.[14]
All the laboratory tests were also done on the control 
samples that had been matched with age and sex with the 
subjects.
Data analysis
Data was analyzed by SPSS version 13. The mean, ranges, 
and standard deviation of the coagulation values in steady 
state were compared with values of normal hemoglobin 
genotype using the ANOVA test. Correlation between 
hemoglobin concentration, coagulation variables, and 
bleeding time were compared using the Pearson correlation 
variable. Hemoglobin concentration of subjects was 
compared with controls using the Student t test (T). The 
relationship between age, sex, and coagulation profile was 
calculated using the chi-square test. The level of significance 
was set at P≤ 0.05.
Results
Demographics
A total of 150 children aged 6 months to 18 years were 
recruited into the study; 100 were confirmed to have 
hemoglobin SS genotype: 50 of whom were in steady state 
while the remaining 50 were in bone pain crises. The control 
consisted of 50 children within the same age group who had 
hemoglobin AA genotype.
As illustrated in Table 1, the mean ages of subjects in 
steady state was 8.41 yrs ± 4.80, in crises 8.56 yrs ± 5.2, 
and for control 8.39 yrs ± 5.38. The subjects (children 
with SCA) and controls were also well matched for sex; 
males (56%), females (44%) in steady state; males (52%) 
and females (48.0%) in bone pain crises (P = 0.983); 
males (44.0%) and females (56%) in controls (x2 = 0.213, 
P = 0.644).
Coagulation variables of SCA in steady state and 
control
Table 2 shows that prothrombin time, APTT, and thrombin 
time were prolonged in the sickle cell steady state patients 
compared to those of the normal HbAA patients. Platelet 
count was higher in the sickle cell steady state patients 
compared to those of the normal HbAA patients. While 
the bleeding time was of shorter duration in the sickle cell 
steady state patients.
Coagulation variables of SCA subjects in crises and 
steady state
In Table 3, the mean values of the activated partial 
thromboplastin time differed significantly between sickle 
cell patients in steady state (41.6 ± 1.0 secs) and those in 
crises (45.6 ± 1.3 secs). P = 0.036. Other coagulation 
values were within the reference range for both states.
The table shows the normal reference values
N/B Though coagulation parameters among children with 
SCA are prolonged when compared to those with normal 
hemoglobin genotype, it still fell within normal reference 
range.
Discussion
The findings of this study provide further evidence of 
coagulation abnormalities among children with SCA. The 
study shows that children with SCA in steady state have 
a prolonged PT and APTT, when compared with children 
with normal hemoglobin genotype and these are further 
prolonged during  crises. This is in keeping with the findings 
of Richardson[15] et al, who noted prolonged PT and APTT in 
subjects with SCA when compared with normal hemoglobin 
genotype individuals. On the other hand, the significantly 
prolonged aPTT of subjects in crises when compared to 
steady state may be due to the production of cytokines and 
anti-lupus factor which are elaborated during infections 
which in turn activate the intrinsic factors leading to their 
consumption.[6]
However, Babiker[16] and colleagues noted no difference 
between these coagulation variables among subjects and 
control, but later found prolonged levels among children 
with crises after the 4th day of crises. He thus concluded 
that the changes of coagulation levels noted, rather than 
being primarily responsible for the onset of crises, can only 
be secondary changes arising from the etiological factors of 
crises, i.e. stasis and acute phase proteins.
There is also a prolonged thrombin time of subjects when 
compared with control. This is in tandem with the study 
of Ataga et al.[17] in North Carolina who noted high level 
of thrombin generation and depletion of anticoagulant 
proteins. He thus concluded that treatment that could 










<3 5 (10) 4 (8) 6
3–5 6 (12) 6 (12) 7
6–8 9 (18) 11 (22) 10
9–11 9 (18) 7 (14) 8
12–14 13 (26) 12 10
>15 8 (16) 10 (20) 9 (18)
P = 0.983, f = 0.018
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decrease thrombin generation or platelet activation may be 
beneficial in both the treatment of sickle cell disease and 
prevention of complications that characterize the disorder.
It is important to note here that Nsiri et al.[18] noted a 
shortened thrombin time among 28 children with SCA 
which is contrary to all the findings above. He noted 
that TT was constantly shortened in the steady state and 
therefore concluded that the shortened value could be due 
to the presence of circulating activated clotting factors in 
SCA and also an elaborated tissue plasminogen activator 
(t-PA) inhibitor levels which create an imbalance of the 
profibrinolytic and antifibrolytic systems. The results of 
Nsiri may be inconclusive due to the small sample size used.
Bleeding time among both SCA in steady state was found 
in this study to be shorter than those of normal hemoglobin 
genotype. This shortened bleeding time among SCA 
children could be due to platelet hyperaggregation. This 
was similar to a study by Maina[19] et al, in Kenya, who noted 
an increased platelet aggregation time among patients in 
steady state when compared to control. The prolonged 
coagulation profile and shortened bleeding time is similar 
to that of Ataga[17] et al, who noted a curious paradox 
between these variables and traced it to nature’s way of 
arresting bleeding in sickle cell patients.
Children with SCA have higher platelet count when 
compared with those with normal hemoglobin genotype. 
This is in keeping with the findings of Kenny[20] et al, who 
detected a significant increase in platelet number among 
16 sickle cell adults when compared with controls. He 
noted similar changes among 12 splenectomized patients 
without SCA. The reason for this rise is traceable to the 
increased circulating population of young metabolically 
active platelets resulting from autosplenectomy. Although 
the platelet count among SCA children is higher than those 
with normal hemoglobin genotype in this study, they still 
fall within normal reference ranges.
The study confirms that though children with SCA in steady 
state have prolonged coagulation indices when compared with 
those with normal hemoglobin genotype, their coagulation 
values still fall within the reference ranges. It is also 
recommended that children with this disorder be screened for 
coagulation profile especially when in vaso-occlusive crises.
In addition, one should have a high index of suspicion of 
possible bleeding or thromboembolic episodes among these 
children especially when they are prepared for surgical 
procedures; this makes it expedient for screening for such 
coagulation variables.
Conclusion
The study confirms that though children with sickle cell 
anaemia in steady state have prolonged coagulation indices 
when compared with those with normal haemoglobin 
genotype, coagulation values still fall within the reference 
ranges.
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